Ezose Sciences has entered into a biotech partnering deal with Kyowa Hakko Kirin, a big pharma company, to collaborate on glycomics studies using Ezose’s proprietary GlycanMap technology platform
.

Kyowa Hakko Kirin will fund several glycan-biomarker and other discovery projects, with an option for further research and development in the light of this biotech partnering deal.

Other details of the biotech partnering agreement were not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on Kyowa Hakko Kirin deals in pharma, biotech, life science partnering deal news, insights and glossary

Related reports: Partnering Deals and Alliances with Kyowa Hakko Kirin

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more